GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2006

MedImmune Inks Partnership to Strengthen Inflammatory Disease Pipeline

  • MedImmune and BioWa will develop and commercialize new inflammatory disease therapies targeting the interleukin-5 (IL-5) receptor, under a licensing and collaboration agreement. Initially, the companies will focus on developing BIW-8405, a Mab currently in Phase I studies in patients with asthma.

    BIW-8405 was developed utilizing BioWa's Potelligent™ technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies. The molecule aims to directly deplete eosinophils, a class of white blood cells implicated in the pathology of asthma and other inflammatory diseases. Additionally, BIW-8405 has the potential to neutralize the activity of IL-5, which is believed to play a key role in the growth and development of eosinophils.

    BioWa will receive an undisclosed upfront payment, milestone payments, and royalties on any future marketed products. BioWa will have exclusive marketing rights in Japan and certain countries in Asia for potential products developed as a result of the agreement. MedImmune will have exclusive marketing rights to these products for the U.S., Europe, and all other countries.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?